180 Participants NeededMy employer runs this trial

Holmium Laser Treatments for Enlarged Prostate

AM
Overseen ByAlyssa McDonald, MPH
Age: 18+
Sex: Male
Trial Phase: Academic
Sponsor: Northwestern University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.

Who Is on the Research Team?

PX

Perry Xu, MD

Principal Investigator

Northwestern University

Are You a Good Fit for This Trial?

This trial is for people with bothersome urinary symptoms from an enlarged prostate who are scheduled to have HoLEP surgery. Participants need internet access and a device to complete online questionnaires.

Inclusion Criteria

Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)
I am having HoLEP surgery for bothersome urinary symptoms.

Exclusion Criteria

Patients unable to read/speak English
Patients who do not have internet access to complete postoperative surveys
I am unable to make my own medical decisions.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo the HoLEP procedure using either the Moses 2.0 or Magneto 150 holmium laser

During surgery

Follow-up

Participants are monitored for safety and effectiveness after the surgical procedure

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Magneto 150 holmium laser
  • Moses 2.0 holmium laser

Trial Overview

The study compares two types of holmium lasers, Magneto 150 and Moses 2.0, used during HoLEP surgery for enlarged prostate, to see which one reduces bleeding time better. Patients are randomly assigned to either laser group.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Magneto 150Experimental Treatment1 Intervention
Group II: Moses 2.0Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Northwestern University

Lead Sponsor

Trials
1,674
Recruited
989,000+

Cook Group Incorporated

Industry Sponsor

Trials
92
Recruited
15,500+

Carl Cook

Cook Group Incorporated

Chief Executive Officer since 2011

Bachelor's degree in Engineering from Purdue University, MBA from the University of Iowa

Dr. John A. Kaufman

Cook Group Incorporated

Chief Medical Officer since 2023

MD